IFNG and graft versus host disease: However, xenograft mice in both TSLPRCART treatment groups subsequently died at approximately day 35 without detectable human ALL, but with robust T cell expansion and increasing IFN-γ levels (Fig. 4A–C, orange), potentially related to mortality from xenogeneic graft-versus-host disease (GVHD) [42].